CClinicalTrials.gg
Status unknownNCT04784026Updated Mar 5, 2021

Dual Task Gait Performance in Pediatric Oncology Patients

An observational study in Pediatric Cancer, sponsored by Afyonkarahisar Health Sciences University. Status unknown at 1 site in Turkey. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-05.

Sponsored by Afyonkarahisar Health Sciences University · Observational

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
6 Years to 18 Years
Sex
All
01

Study summary

Cancer incidence, which is recognized as the leading cause of death in children worldwide, is gradually increasing.

Most studies on children who survive cancer show that the disease and its treatment have side effects and long-term late effects on the musculoskeletal system, physical function, gait and cognitive skills.

Therefore, dual task gait performance, in which cognitive and motor tasks are performed simultaneously, may be affected in pediatric oncology patients. The aim of this study is to compare gait performance in single and dual task conditions in pediatric oncology patients with healthy controls.

Read the detailed description

Cancer incidence, which is recognized as the leading cause of death in children worldwide, is gradually increasing. About 300,000 children aged 0 to 19 are diagnosed with cancer each year, according to the international study where the International Agency for Research on Cancer collected data on neoplasms (malignant and non-malignant) diagnosed in individuals under 20 years of age between 2001-2010.

Most studies on children who survive cancer show that the disease and its treatment have side effects and long-term late effects on the musculoskeletal system, physical function, gait and cognitive skills. According to the study of Beulertz et al. (2016), active ankle dorsiflexion limitation, gait disturbances and decrease in walking efficiency were observed in all pediatric oncology patients, which have an important role in walking, not limited to children with bone tumors and central nervous system tumors.Intensive chemotherapy (eg methotrexate) and the use of radiation are thought to cause damage to cortical and subcortical white matter, resulting in late effects. Symptoms consistent with attention deficit disorder and mental processing speed, working memory, executive function and memory deficits put cancer survivors at an intellectual and academic disadvantage.

Therefore, dual task gait performance, in which cognitive and motor tasks are performed simultaneously, may be affected in pediatric oncology patients. The aim of this study is to compare gait performance in single and dual task conditions in pediatric oncology patients with healthy controls.

02

Conditions studied

  • Pediatric Cancer

Keywords

  • pediatrics
  • neoplasms
  • gait
03

In context

Lead sponsor

Afyonkarahisar Health Sciences University is the lead sponsor of 107 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

In this study, inpatient and outpatient children diagnosed with cancer in Afyonkarahisar Health Sciences University Health Application and Research Center Pediatric Hematology-Oncology Clinics will form the case group of the study.

Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association to do sports and who have recently registered will form the control group of the research.

Inclusion criteria

Healthy control group:

  • Being in the age range of 6-18,
  • To be physically, cognitively and mentally healthy,
  • Open to communication enough to understand questions,
  • Speaking and understanding Turkish,
  • Approval has been obtained from the child and his / her family for the study and who agrees to participate in the study,

Case group:

  • Able to walk alone without any walking aid,
  • Open to communication enough to understand questions,
  • Speaking and understanding Turkish,
  • Approval has been obtained from the child and his / her family for the study and who agrees to participate in the study,
  • Children between the ages of 6-18 will be included in the study

Exclusion criteria

Exclusion Criteria:

Healthy control group:

  • Any orthopedic or neurological impairment that would prevent walking;
  • Having any mental disability that prevents cognitive task

Case group:

  • Staying in an isolated room or having risk of infection (neutropenic, etc.),
  • Any orthopedic or neurological impairment that could prevent walking;
  • Having any mental disability that prevents cognitive task,
  • Individuals with malignant hypertension or unstable heart disease (eg congestive heart failure) will not be included in the study.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Control Group

    Healthy children who come to Afyonkarahisar Ege Youth and Sports Club Association for the purpose of sports, newly registered and between the ages of 6-18 will constitute the control group of the study.

    Other: Gait assessment (single) · Other: Dual task gait assessment (motor+motor) · Other: Dual tak gait assessment (motor+cognitive)

  • Case Group

    The sample of the study will be inpatient and outpatient pediatric patients between the ages of 6-18 who have been diagnosed with cancer in the Pediatric Hematology-Oncology Clinics of Afyonkarahisar Health Sciences University Health Application and Research Center Department of Pediatrics.

    Other: Gait assessment (single) · Other: Dual task gait assessment (motor+motor) · Other: Dual tak gait assessment (motor+cognitive)

Interventions

  • OtherGait assessment (single)

    The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.

  • OtherDual task gait assessment (motor+motor)

    The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.

  • OtherDual tak gait assessment (motor+cognitive)

    The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.

06

What researchers measure

Primary outcomes

  1. gait speed

    Gait speed is the time one takes to walk a specified distance on level surfaces over a short distance.

    Time frame: 20 minutes

  2. cadence

    Cadence is the rate at which a person walk, expressed in steps per minute. The average cadence is 100 - 115 steps/min.

    Time frame: 20 minutes

  3. stride length

    Stride length is defined as the distance between successive ground contacts of the same foot.

    Time frame: 20 minutes

07

Study locations

1 of 1 sites recruiting
  • Emel Taşvuran Horata
    Afyonkarahisar, 03030, Turkey
    • EMEL TAŞVURAN HORATA, PhD · Contact · ethorata@gmail.com · +905547759663
    • · Contact · ethorata@gmail.com
    • EMEL TAŞVURAN HORATA, PhD · Principal investigator
    • Hamide Nur ÇEVİK ÖZDEMİR, PhD · Sub investigator
    • Yunus Emre KUNDAKCI, PhD · Sub investigator
    • İbrahim EKER, PhD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04784026
Lead sponsor
Afyonkarahisar Health Sciences University
Responsible party
Emel Taşvuran Horata (PhD; Assistant Professor, Afyonkarahisar Health Sciences University) — Principal investigator
First posted
Mar 5, 2021
Start date
Mar 1, 2021
Primary completion
Mar 20, 2023 (estimated)
Completion
Mar 20, 2023 (estimated)
Last update
Mar 5, 2021

Study contacts

EMEL TAŞVURAN HORATA, PhD
Contact
ethorata@gmail.com
05547759663
EMEL TAŞVURAN HORATA, PhD
principal investigator · Afyonkarahisar Health Science University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion